PhysIQ is onboarding clinical trial sites that are interested in leveraging our solution in clinical trials. Learn More About Our Clinical Trial Partner Program

Who We Are

The physIQ team has been successfully developing highly innovative solutions for monitoring the health of complex systems for more than a decade.  Our core management team members are pioneers of IoT, with unparalled experience in developing and commercializing transformational machine-learning analytics for time-series sensor data...

Peter Fitzgerald, MD, PhD, FACC


Dr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. He is professor in both the Departments of Medicine and Engineering at Stanford. Dr. Fitzgerald’s laboratory focuses on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 150 clinical trials, published over 450 manuscripts/chapters, and lectures worldwide. He has trained over 150 post-docs in Engineering and Medicine and heads the Stanford/Asia MedTech innovation program. Peter has been principal/founder of 18 medical device companies and has transitioned 12 of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device start-ups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, he was on the founding team of LVP Capital, a venture firm, focused on medical device and biotechnology start-ups. In 2009, he co-founded TriVentures, an incubator/venture fund for early stage medical technology in Israel.

Contact us and transform the future of real-world patient insight.

At physIQ, we welcome the opportunity to speak with potential customers, partners, or anyone with an interest in learning more about the transformative potential of our technology.

CONTACT US